Does Rallies show Form 4 insider transactions for OKYO?

Yes. Rallies tracks OKYO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OKYO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OKYO. It does not provide personalized investment advice.

OKYO (OKYO Pharma Limited Ordinary Shares) Stock Analysis - Insider Trades

OKYO Pharma Limited Ordinary Shares (OKYO) is a publicly traded Healthcare sector company. As of May 19, 2026, OKYO trades at $1.59 with a market cap of $82.39M and a P/E ratio of 0.00. OKYO moved +0.00% today. Year to date, OKYO is -28.70%; over the trailing twelve months it is +7.43%. Its 52-week range spans $0.90 to $3.35. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces OKYO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OKYO stock inside the company?

Recent OKYO insider activity includes BRANCACCIO JOHN P bought 16.67K, CERRONE GABRIELE M bought 5.80M, JACOB GARY S bought 12.50K, CERRONE GABRIELE M bought 37.50K, and CERRONE GABRIELE M bought 25.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OKYO Key Metrics

Key financial metrics for OKYO
Metric	Value
Price	$1.59
Market Cap	$82.39M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.35
52-Week Low	$0.90
Volume	11.05K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Recent OKYO Insider Trades

BRANCACCIO JOHN P bought 16.67K (~$25.00K) on Sep 15, 2023.
CERRONE GABRIELE M bought 5.80M (~$440.80K) on May 19, 2022.
JACOB GARY S bought 12.50K (~$50.00K) on May 19, 2022.
CERRONE GABRIELE M bought 37.50K (~$150.00K) on May 19, 2022.
CERRONE GABRIELE M bought 25.00K (~$96.75K) on May 17, 2022.

Latest OKYO News

OKYO Pharma Appoints MD PhD Expert, Secures Fast Track for 150-Patient Phase 2b/3 — May 19, 2026
OKYO Pharma to Present at Eyecelerator and ARVO with Urcosimod Phase 2 Data — Apr 29, 2026
OKYO Pharma Chairman Buys 10,119 Shares at $1.59, Boosts Stake to 10.5M — Mar 19, 2026
OKYO’s 0.05% Urcosimod Achieves −4.5 QoL Improvement in Phase 2a Trial — Mar 18, 2026
OKYO Pharma to Present First-in-Human Urcosimod Phase 1 Results at ARVO 2026 — Feb 23, 2026

OKYO Analyst Consensus

1 analysts cover OKYO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.

Common questions about OKYO

Who is trading OKYO stock inside the company?: Recent OKYO insider activity includes BRANCACCIO JOHN P bought 16.67K, CERRONE GABRIELE M bought 5.80M, JACOB GARY S bought 12.50K, CERRONE GABRIELE M bought 37.50K, and CERRONE GABRIELE M bought 25.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OKYO?: Yes. Rallies tracks OKYO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OKYO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OKYO. It does not provide personalized investment advice.